Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study

Yongxian Hu, Jiqin Zhang, Mingming Zhang, Wei Li, Wenjun Wu, Jiazhen Cui, Guoqing Wei, Bing Du, Mingyao Liu, He Huang

Blood (2022) 140 (Supplement 1): 7491–7492.

https://doi.org/10.1182/blood-2022-156137

Published: 2022

Journal Articles

Genomic and Transcriptomic Profiling Reveal the Mechanism and Risk Factors of CD19-Negative Relapse after CAR-T Cell Therapy

Ruimin Hong, Linghui Zhou, Ye Meng, Mingming Zhang, Houli Zhao, Jiazhen Cui, Simao Huang, Yongxian Hu, He Huang

Blood (2022) 140 (Supplement 1): 6354–6355.

https://doi.org/10.1182/blood-2022-164955

Published: 2022

Journal Articles

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia

Yiyun Wang, Linqin Wang, Mi Shao, Xiangjun He, Yanan Yue, Yixuan Zhou, Luhan Yang, He Huang, Yongxian Hu

Blood (2022) 140 (Supplement 1): 12685.

https://doi.org/10.1182/blood-2022-166420

Published: 2022

Journal Articles

Muticenter Retrospective Comparable Study of Prophylactic Versus Preemptive Modified Donor Lymphocyte Infusion for Patients with High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Luxin Yang, Xiaoyu Lai, Ting Yang, Ying Lu, Lizhen Liu, Jimin Shi, Yanmin Zhao, Yibo Wu, Yi Chen, Jian Yu, Haowen Xiao, Guifang Ouyang, Jinhua Ren, Junjie Cao, Yongxian Hu, Yamin Tan, Zhen Cai, He Huang, Yi Luo

Blood (2022) 140 (Supplement 1): 7676–7677.

https://doi.org/10.1182/blood-2022-166759

Published: 2022

Journal Articles

Central Nervous System Relapse after CAR-T Cell Therapy in B-Cell Malignancies

Tianning Gu, Wenfa Huang, Lei Wang, Yuqi Li, Lixin Wang, Yongxian Hu, He Huang

Blood (2022) 140 (Supplement 1): 13220–13221.

https://doi.org/10.1182/blood-2022-168477

Published: 2022

Journal Articles

Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial

Jingjing Feng, Yongxian Hu, Mingming Zhang, Heng Cao, Yini Ke, Huijun Xu, Jiazhen Cui, Yanlei Zhang, Alex Hongsheng Chang, Jin Lin, Guoqing Wei, He Huang

Blood (2022) 140 (Supplement 1): 10335–10336.

https://doi.org/10.1182/blood-2022-169265

Published: 2022

Journal Articles

MEK Inhibition in CAR-T Cells Prevents Exhaustion and Terminal Differentiation Via Downregulating C-Fos and JunB

Blood (2022) 140 (Supplement 1): 626–627.

https://doi.org/10.1182/blood-2022-158646

Published: 2022

Journal Articles

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Blood (2022) 139 (23): 3376–3386.

https://doi.org/10.1182/blood.2021013733

Published: 2022

Includes: Supplemental data

Journal Articles

Venetoclax-Ponatinib for T315I/Compound-Mutated Ph+Acute Lymphoblastic Leukemia

Huafeng Wang, Jiejing Qian, Chang Yang, Yi Zhang, Yungui Wang, Ting Shi, Yongxian HU, Liping Mao, Xiujin Ye, Fang Liu, Zhenfang Xi, Lihong Shou, Caiyun Fu, Hua Naranmandura, Jie Jin, Hong-Hu Zhu

Blood (2021) 138 (Supplement 1): 3395.

https://doi.org/10.1182/blood-2021-152836

Published: 2021

Journal Articles

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 547.

https://doi.org/10.1182/blood-2021-152576

Published: 2021

Journal Articles

Predictive Value of Next-Generation Sequencing-Based Minimal Residual Disease after CAR-T Cell Therapy

Yue Huang, Houli Zhao, Mi Shao, Linghui Zhou, Guoqing Wei, Wenjun Wu, Alex Hong Chang, Tao Sun, Yongxian HU, He Huang

Blood (2021) 138 (Supplement 1): 2842.

https://doi.org/10.1182/blood-2021-149928

Published: 2021

Journal Articles

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy

Ruimin Hong, Houli Zhao, MD, Yiyun Wang, Yu Chen, Hongliu Cai, Yongxian Hu, MD, Guoqing Wei, MD, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139007

Published: 2020

Journal Articles

CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study

Yongxian Hu, MD, Yanlei Zhang, Houli Zhao, MD, Yiyun Wang, Arnon Nagler, MD, Alex Hong Chang, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-143239

Published: 2020

Journal Articles

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Yongxian Hu, MD, Yali Zhou, Mingming Zhang, MD, Wengang Ge, Yi Li, MD, Li Yang, MD, Guoqing Wei, MD, Lu Han, Hao Wang, Xingwang Zhang, PhD, Jiangtao Ren, PhD, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 52.

https://doi.org/10.1182/blood-2020-142262

Published: 2020

Journal Articles

Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry

Yongxian Hu, MD, Zhang Yanlei, Guoqing Wei, Chang alex Hong, He Huang

Blood (2019) 134 (Supplement_1): 1859.

https://doi.org/10.1182/blood-2019-130341

Published: 2019

Journal Articles

Galectin-9 from Bone Marrow Mesenchymal Stromal Cells Mediates Immunosuppression on Chimeric Antigen Receptor T Cells

Xinyi Teng, BS, Hao Zhang, MD, Zuyu Liang, MD, Mi Shao, MD, Xiujian Wang, MD, Lijuan Ding, MD, Jiazhen Cui, msc, Yongxian Hu, MD, He Huang, MD PhD

Blood (2019) 134 (Supplement_1): 5609.

https://doi.org/10.1182/blood-2019-131680

Published: 2019

Journal Articles

Pre-Transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy Followed By Haploidentical HSCT for Relapsed/Refractory Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study

Yongxian Hu, MD, Zhao Houli, Wei Guoqing, Yi Luo, MD, Ji Min Shi, Jing Chen, Zhang Qing, Song Xianmin, Lei Xiao, PhD, Alex Hong Chang, Didier Blaise, MD PhD, Mohamad Mohty, MD PhD, He Huang

Blood (2019) 134 (Supplement_1): 3213.

https://doi.org/10.1182/blood-2019-128399

Published: 2019

Journal Articles

Cytokine Release Syndrome Is an Independent Risk Factor Associated with Platelet Transfusion Refractoriness after CAR-T Treatment for Relapsed/Refractory Acute Lymphoblast Leukemia

Yadan Liu, graduate student, Yongxian Hu, MD, He Huang

Blood (2019) 134 (Supplement_1): 2448.

https://doi.org/10.1182/blood-2019-129678

Published: 2019

Journal Articles

Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT

Jimin Shi, MD, Liqin Cao, MD, Yi Luo, MD, Yanmin Zhao, MD, Yamin Tan, MD, Jian Yu, MD, Xiaoyu Lai, MD, Yuanyuan Zhu, MD, Yongxian Hu, MD, Jingsong He, MD, Jie Sun, MD, Weiyan Zheng, MD, Guoqing Wei, MD, He Huang

Blood (2019) 134 (Supplement_1): 2668.

https://doi.org/10.1182/blood-2019-127594

Published: 2019

Journal Articles

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

Feng Zhu, Yongxian Hu, MD, Wei Guoqing, He Huang, Wenjun Wu, MD

Blood (2019) 134 (Supplement_1): 3220.

https://doi.org/10.1182/blood-2019-129649

Published: 2019

NARROW

High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study

Genomic and Transcriptomic Profiling Reveal the Mechanism and Risk Factors of CD19-Negative Relapse after CAR-T Cell Therapy

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia

Muticenter Retrospective Comparable Study of Prophylactic Versus Preemptive Modified Donor Lymphocyte Infusion for Patients with High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Central Nervous System Relapse after CAR-T Cell Therapy in B-Cell Malignancies

Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial

MEK Inhibition in CAR-T Cells Prevents Exhaustion and Terminal Differentiation Via Downregulating C-Fos and JunB

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Venetoclax-Ponatinib for T315I/Compound-Mutated Ph+Acute Lymphoblastic Leukemia

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Predictive Value of Next-Generation Sequencing-Based Minimal Residual Disease after CAR-T Cell Therapy

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy

CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry

Galectin-9 from Bone Marrow Mesenchymal Stromal Cells Mediates Immunosuppression on Chimeric Antigen Receptor T Cells

Pre-Transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy Followed By Haploidentical HSCT for Relapsed/Refractory Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study

Cytokine Release Syndrome Is an Independent Risk Factor Associated with Platelet Transfusion Refractoriness after CAR-T Treatment for Relapsed/Refractory Acute Lymphoblast Leukemia

Maintenance Sorafenib Is Superior to Prophylactic DLI in Improving the Prognosis of FLT3-ITD-Positive AML after Allogeneic HSCT

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only